Identification of HLA class II-restricted T cell epitopes in public neoantigens from common cancer mutations enables shared peptide vaccines applicable to multiple patients.
Key findingIdentification of HLA class II-restricted T cell epitopes in public neoantigens from common cancer m
What the researchers found
Identification of HLA class II-restricted T cell epitopes in public neoantigens from common cancer mutations enables shared peptide vaccines applicable to multiple patients.
Why it matters
Relevant to peptide therapeutics.
The numbers in context
Study focused on ESR1 and PIK3CA mutations — two of the most common genetic changes in hormone receptor-positive breast cancer.
How the study worked
In publication.
Who was studied
Hormone receptor-positive breast cancer mutations (preclinical research)
What this study cannot tell us
In publication.
How to read the evidence
Based on design.
When this study was published
Published in 2025.
The bigger picture
Advances peptide evidence.
Questions still open
- Long-term implications?
- Evidence comparison?
- Next steps?
Common questions
What does this mean?
How reliable?
Read the original research
HLA class II-restricted T cell epitopes in public neoantigens of ESR1 and PIK3CA in breast cancer.
BMC cancer, 25(1), 610
Citation
Ando, Yukari; Miyadera, Hiroko; Bando, Hiroko; Hashimoto, Sachie; Noguchi, Emiko; Hara, Hisato. (2025). HLA class II-restricted T cell epitopes in public neoantigens of ESR1 and PIK3CA in breast cancer.. BMC cancer, 25(1), 610. https://doi.org/10.1186/s12885-025-13992-6